Curcumin for Prevention of Relapse in Patients With Ulcerative Colitis
Status:
Unknown status
Trial end date:
2021-04-01
Target enrollment:
Participant gender:
Summary
UC is a chronic inflammatory bowel disorder with relapsing and remitting course. The efficacy
of mesalazine in preventing relapse in patients with UC is well-known and supported by
randomized studies. However, mesalazine can be associated with side-effects. In addition,
drug compliance is suboptimal, especially when disease is not active. Curcumin is a natural
phytochemical derived from the Indian spice turmeric. It is widely used, has potent
anti-inflammatory, anti-oxidant and anti-tumour properties.
The aims of this double-blind, placebo-controlled randomized trial is to assess the efficacy
of curcumin in the prevention of relapse in patients with ulcerative colitis (UC).